Related by context. All words. (Click for frequent words.) 75 PCa 75 prostate cancer CaP 74 urothelial carcinoma 73 prostate carcinoma 73 urothelial cancer 71 colorectal adenoma 71 differentiated thyroid 70 renal tumors 70 HNSCC 70 epithelial tumors 69 epithelial ovarian cancer 69 colorectal carcinoma 69 recurrent glioblastoma multiforme 69 Radical prostatectomy 69 gastric adenocarcinoma 68 angiographically 68 nodal metastasis 68 seminoma 68 metastatic lymph nodes 68 malignant lymphoma 68 F FDG PET 68 T1a 68 cutaneous melanoma 68 gastric carcinoma 68 carcinoid tumors 68 serous ovarian cancer 68 thyroid nodules 68 malignant pleural mesothelioma 68 prognostic variables 68 CIN2 + 68 antiangiogenic therapy 68 clinically localized prostate 68 histological subtype 68 ductal adenocarcinoma 67 immunohistochemical staining 67 breast carcinoma 67 pancreatic adenocarcinoma 67 prognostic indicator 67 FDG PET imaging 67 microsatellite instability 67 ovarian malignancy 67 NMIBC 67 prognostic biomarker 67 Haptoglobin 67 thyroid carcinoma 67 breast carcinomas 67 neoplasias 67 hepatic fibrosis 67 CP CPPS 67 prognostic significance 67 malignant ascites 67 postoperative AF 67 papillary thyroid carcinoma 67 androgen deprivation 67 Adjuvant chemotherapy 67 mucinous 67 gefitinib Iressa 67 cTnI 67 thymoma 67 Immunohistochemical staining 67 liver metastasis 67 histologic subtype 67 prognostic indicators 67 metastatic neuroendocrine tumors 67 neoplasm 67 hepatocellular carcinomas 67 peritoneal carcinomatosis 67 prostate carcinomas 67 thyroglobulin 67 paragangliomas 67 histologically confirmed 66 serum PSA 66 esophageal squamous cell carcinoma 66 prospectively randomized 66 CTEPH 66 hyperoxaluria 66 FDG-PET/CT 66 carcinomatosis 66 papillary renal cell carcinoma 66 HER2 overexpression 66 diagnostic biomarker 66 relapsed MM 66 ovarian carcinoma 66 tumor histology 66 murine models 66 carcinoid tumor 66 endometrial hyperplasia 66 SSc 66 KRAS status 66 colorectal liver metastases 66 ABCB1 66 biochemical marker 66 adjuvant radiotherapy 66 locoregional recurrence 66 perfusion abnormalities 66 tumor necrosis 66 liposomal amphotericin B 66 prostate cancer CRPC 66 skeletal metastases 66 renal cell carcinomas 66 hyperplastic 66 leukemia AML 66 Papillary 66 paricalcitol 66 leiomyomas 66 bladder tumors 66 papillary carcinoma 66 cytologic 66 abacavir Ziagen 66 subclinical atherosclerosis 66 hepatocellular carcinoma HCC 66 cervical carcinoma 66 stratifying patients 66 Vidaza azacitidine 66 cisplatin resistant 66 aminotransferase 66 mycosis fungoides 66 polycythemia vera PV 66 pheochromocytoma 66 neuroendocrine cancers 66 PKC# 66 esophagogastric 66 HIV HCV coinfected 66 unresectable tumors 66 HER2 expression 66 chemosensitivity 66 lymph node metastasis 66 LHRH receptor positive 66 Sjögren syndrome 65 cancer mCRC 65 thiopurine 65 FDG uptake 65 MYCN amplification 65 Hurthle cell 65 invasive ductal 65 chemoradiotherapy 65 superficial bladder cancer 65 nonsmall cell lung cancer 65 operable breast cancer 65 colorectal neoplasms 65 intact parathyroid hormone 65 squamous cell carcinoma SCC 65 interleukin IL -# 65 metaplasia 65 nonmetastatic prostate cancer 65 urography 65 Prognostic factors 65 GnRH agonist 65 induced sputum 65 Subgroup analysis 65 KRAS mutation 65 lymphocytosis 65 thromboembolic disease 65 cardiac troponin 65 Enzastaurin 65 HGPIN 65 Candida infection 65 antigen PSA levels 65 osteopenic 65 immunohistochemical analysis 65 adenomatous 65 cardiac troponin T 65 lymphoma subtypes 65 myeloproliferative diseases 65 recurrent venous thromboembolism 65 hematopoietic cancers 65 metachronous 65 caspofungin 65 immunohistochemical 65 #F FDG PET 65 endometrial carcinoma 65 microvessel density 65 basal cell carcinoma BCC 65 QTc prolongation 65 node metastases 65 PTLD 65 nonmetastatic 65 bronchogenic carcinoma 65 histologically proven 65 antitumor effect 65 carotid plaques 65 pain palliation 65 renal artery stenosis 65 prostate adenocarcinoma 65 Legg Calvé Perthes disease 65 AST ALT 65 demonstrated antitumor activity 65 bone scintigraphy 65 HER2 amplification 65 hyperparathyroidism 65 colorectal adenocarcinoma 65 ADPKD 65 distant metastasis 65 tumorigenicity 65 erythropoietic 65 renal carcinoma 65 ASCUS 65 symptomatic paroxysmal AF 65 thyrotoxicosis 65 thromboembolism 65 pT2 65 multivariate Cox 65 Kinoid 65 node metastasis 65 transabdominal 65 perioperative morbidity 65 cervical lymph nodes 65 T2DM 65 metastatic malignant melanoma 65 chronic prostatitis 65 Computed tomography 65 Lymph node 65 Pemetrexed 65 somatostatin analogs 65 colorectal cancer CRC 65 Surgical resection 65 Prostatitis 64 extracapsular extension 64 GH deficiency 64 neuroendocrine carcinoma 64 MGd 64 choroidal neovascularization 64 lymph node metastases 64 CC genotype 64 mutated K ras 64 bladder carcinoma 64 immunocompetent 64 HER2 positive cancers 64 imatinib Gleevec 64 hyperinsulinemic euglycemic clamp 64 GISTs 64 grade cervical intraepithelial 64 cutaneous squamous cell carcinoma 64 myelofibrosis polycythemia vera 64 refractory prostate cancer 64 pulmonary metastases 64 hamartomas 64 diabetes mellitus DM 64 Degarelix 64 intestinal metaplasia 64 chlamydial 64 antiproliferative effects 64 thalidomide Thalomid 64 biochemical recurrence 64 lipid abnormalities 64 obstructive coronary artery 64 retrospective cohort 64 flavopiridol 64 Glioblastoma Multiforme 64 hamartoma 64 radiotherapy RT 64 ALA PDT 64 carotid stenosis 64 pulmonary hypertension PH 64 parathyroid 64 plasma kallikrein 64 coronary stenosis 64 latent celiac disease 64 metastatic gastric 64 incidentalomas 64 histone deacetylase inhibitor 64 INCB# [003] 64 recurrent glioblastoma multiforme GBM 64 bioavailable testosterone 64 mitochondrial toxicity 64 prospectively defined 64 intratumoral 64 BRAF V#E mutation 64 5alpha reductase 64 murine model 64 histopathologic examination 64 serum biomarkers 64 TPMT 64 acute lymphoblastic 64 treat benign prostatic 64 adenoma 64 clinicopathological 64 galiximab 64 EGFR tyrosine kinase inhibitors 64 cervical neoplasia 64 imatinib resistance 64 primary hyperparathyroidism 64 artery stenosis 64 cilengitide 64 immunochemical fecal occult 64 PHPT 64 busulfan 64 hyperhomocysteinemia 64 specific antigen PSA 64 Lp PLA 2 64 malignant neoplasm 64 lymphoproliferative disorders 64 alpha fetoprotein AFP 64 MALT lymphoma 64 isoprostane 64 basal cell nevus syndrome 64 Hepatocellular Carcinoma HCC 64 VerifyNow P#Y# 64 lactate dehydrogenase LDH 64 thrombocytopenic 64 carcinoid 64 Immunohistochemical analysis 64 pegylated liposomal doxorubicin 64 depsipeptide 64 hyperintense lesions 64 gadolinium enhanced 64 haematologic 64 bortezomib Velcade 64 ductal carcinomas 64 hemodilution 64 leiomyoma 64 haematological toxicity 64 Squamous 64 cranial irradiation 64 invasive lobular 64 neovascularisation 64 onset diabetes mellitus 64 GnRH agonists 64 androgen ablation 64 biochemical relapse 64 bleomycin 64 receptor tyrosine kinase inhibitor 64 K ras mutations 64 sorafenib Nexavar 64 genetic polymorphisms 64 adenocarcinomas 64 Multivariate logistic regression 64 medullary thyroid carcinoma 64 primary aldosteronism 64 PCNSL 64 pelvic lymphadenectomy 64 antigen PSA 64 thromboembolic complications 64 BMS# 64 arterial calcification 64 urolithiasis 64 pulmonary metastasis 64 anti JCV antibodies 64 transcranial Doppler ultrasound 64 hepatoma 64 hormone receptor negative 64 radiographic findings 64 scintigraphic 64 serum cortisol 64 adrenalectomy 64 nodal metastases 64 biliary tract cancer 64 fosbretabulin 64 ABL1 64 cytotoxicity assays 63 CSF biomarkers 63 Epstein Barr virus EBV 63 gemcitabine Gemzar 63 gastric carcinomas 63 upper gastrointestinal bleeding 63 transthyretin amyloidosis 63 liver transplant recipients 63 estrogen receptor ER 63 germline mutations 63 Langerhans cell histiocytosis 63 neovascular 63 cTnT 63 carcinoids 63 adrenal masses 63 lymphadenectomy 63 aortic atherosclerosis 63 systemic amyloidosis 63 fluorodeoxyglucose positron emission tomography 63 Estrogen Receptor 63 immunostaining 63 relapsing remitting MS RRMS 63 esophageal carcinoma 63 diagnostic modality 63 pediatric malignancies 63 eosinophil count 63 ZACTIMA 63 CaP 63 macroalbuminuria 63 lobular carcinoma 63 decompensated cirrhosis 63 percutaneous biopsy 63 vestibular schwannomas 63 gastric cancers 63 erlotinib Tarceva ® 63 sonographically guided 63 adriamycin 63 breast cancer subtypes 63 Androgen deprivation therapy 63 malignant nodules 63 syngeneic 63 renal scarring 63 p# biomarker 63 PSA nadir 63 hormone receptor status 63 azacytidine 63 smoldering myeloma 63 histologic diagnosis 63 carotid IMT 63 prognostic marker 63 pancreatic carcinoma 63 mRCC 63 myeloperoxidase 63 elevated LDH 63 gastrointestinal stromal tumors GISTs 63 peritoneal cancer 63 spiral computed tomography 63 locoregional 63 trastuzumab Herceptin ® 63 T1DM 63 flurpiridaz F 63 Adjuvant therapy 63 seminomas 63 HRCT 63 thyrotropin 63 metastatic bladder 63 symptomatic benign prostatic 63 taxane resistant 63 pCR 63 metastatic renal cell carcinoma 63 hemodialysis patients 63 radical prostatectomy RP 63 cerebral vasospasm 63 nasopharyngeal carcinoma 63 sonographic appearance 63 gene polymorphism 63 metastatic prostate cancer 63 bronchial epithelial cells 63 radioimmunoassay 63 EUS FNA 63 flutamide 63 Fenretinide 63 monocytic 63 vasogenic edema 63 knee osteoarthritis OA 63 differential gene expression 63 GIST tumors 63 hereditary hemochromatosis 63 Xanafide 63 advanced adenoma 63 bevacizumab Avastin ® 63 triiodothyronine 63 tumor recurrence 63 epithelial ovarian 63 Subgroup analyzes 63 trans retinoic acid 63 CYT# potent vascular disrupting 63 BRCA mutation carriers 63 obstructive coronary 63 esophageal gastric 63 T1c 63 cardiac dysfunction 63 semiquantitative 63 idiopathic pulmonary arterial hypertension 63 lymphoid cells 63 etiologic 63 myocardial ischaemia 63 neoplasia 63 Western blotting 63 denileukin diftitox 63 EBV infection 63 Endometrial 63 CT angiography CTA 63 depressive symptomatology 63 prognostic factor 63 PC# cells 63 HBsAg 63 Cytoxan 63 follicular thyroid cancer 63 neutrophil counts 63 thyroid dysfunction 63 duplex ultrasonography 63 metastatic malignant 63 Helicobacter pylori eradication 63 nonalcoholic steatohepatitis NASH 63 ziconotide 63 varicoceles 63 radiolabeled TM# 63 florbetaben 63 pathologic fractures 63 endocrine therapies 63 Hashimoto thyroiditis 63 alkaline phosphatase ALP 63 pretransplant 63 urothelial bladder cancer 63 Toxicities 63 liver histology 63 thrombocytosis 63 glomerular filtration 63 nutlin 3a 63 ertapenem 63 arteriography 63 antinuclear antibodies 63 scintigraphy 63 hyperalgesia 63 endometrial cancers 63 atherosclerotic lesions 63 uterine tumors 63 ERalpha 63 β blockers 63 euthyroid 63 cerebral microbleeds 63 alveolar rhabdomyosarcoma 63 RRM1 63 pentoxifylline 63 oral squamous cell 63 bronchial hyperresponsiveness 63 paroxysmal nocturnal hemoglobinuria 63 lymphadenopathy 63 breast cancer metastasis 63 adrenocortical cancer 63 CMV infection 63 rituximab Rituxan 63 nonmelanoma skin cancers 63 fluorodeoxyglucose 63 pan HDAC inhibitor 63 hepatocellular carcinoma 63 immune modulating 63 Solid Tumours 63 RAS mutations 63 autonomic dysfunction 63 low expressors 63 glycated hemoglobin levels 63 enteroviral infection 63 squamous 63 Sezary syndrome 63 IGFBP 3 63 castrate resistant prostate cancer 63 metastatic pancreatic 63 allogeneic HSCT 63 N telopeptide 63 STRIDE PD 63 GSTP1 63 Deforolimus 63 liver resection 63 Prostate specific antigen 63 MTT assay 63 grade gliomas 63 carcinoembryonic antigen 63 Clusterin 63 thyroid peroxidase 63 TNF α 63 monogenic 63 Fas ligand 63 IgA deficiency 63 mCRC patients 63 glutamyl 63 vinca alkaloid 63 bronchoalveolar 63 ductal cancer 63 neratinib 63 carotid atherosclerosis 63 Cardiotoxicity 62 invasive aspergillosis 62 antiandrogens 62 serum urate levels 62 nephrogenic 62 intravenous bisphosphonates 62 FDG PET 62 MGUS 62 androgen deficiency 62 neutrophil count 62 transthoracic echocardiography 62 HBeAg positive 62 adrenocortical 62 fallopian tube cancers 62 D dimer 62 metastatic lesion 62 urodynamic 62 leukoencephalopathy 62 atrophic gastritis 62 Temsirolimus 62 T#I [002] 62 cholangiocarcinoma 62 molecular abnormalities 62 aromatase inhibitors AIs 62 lung nodule 62 heterozygotes 62 plasma pharmacokinetics 62 LRP5 62 cisplatin chemotherapy 62 hyperacute 62 Intravenous immunoglobulin 62 FVIII inhibitors 62 postoperative complication 62 pretargeting 62 Alkaline Phosphatase 62 mTOR inhibitors 62 noncardiac 62 secondary hyperparathyroidism 62 BEXXAR Therapeutic Regimen 62 autoimmune pancreatitis 62 mTOR inhibition 62 fibroadenomas 62 chronic thromboembolic pulmonary 62 LVNC 62 histopathological 62 rebleeding 62 Insulin detemir 62 invasive candidiasis 62 histologic findings 62 hepatic cirrhosis 62 isoprostanes 62 androgen suppression 62 melanocytic nevi 62 immunopathology 62 chromosomal mutations 62 MSMB 62 bronchoalveolar lavage BAL 62 Cystatin C 62 DCIS ductal carcinoma 62 Glioma 62 Glioblastoma Multiforme GBM 62 clinico pathological 62 pharmacodynamic PD 62 idiopathic myelofibrosis 62 NSCLC tumors 62 hepatorenal syndrome 62 Gleevec resistant 62 B Cell Lymphoma 62 invasive carcinomas 62 mycophenolate mofetil 62 Aplidin 62 immunochemical 62 dimeglumine 62 human chorionic gonadotropin hCG 62 genes differentially expressed 62 ritonavir boosted 62 TRAIL R1 62 genotypic resistance 62 Glucocorticoids 62 POAG 62 riociguat 62 pituitary adenomas 62 idiopathic pulmonary 62 hypothalamic pituitary 62 cervical lesions 62 tumor subtypes 62 Chronic Myelogenous Leukemia CML 62 fallopian tube carcinoma 62 LV dysfunction 62 radioimmunotherapy RIT 62 EBUS FNA 62 membranous nephropathy 62 transvaginal sonography 62 hippocampal atrophy 62 invasive carcinoma 62 intraepithelial 62 immunosuppressive regimen 62 neurocognitive impairment 62 MAGE A3 ASCI 62 transrectal ultrasonography 62 PARP inhibition 62 intravesical therapy 62 prospective multicenter study 62 concurrent chemoradiation 62 sCJD 62 metabolic dysfunction 62 micrometastasis 62 prostate cancer AIPC 62 prostate cancer mCRPC 62 alkylating agent 62 tolerability pharmacokinetics 62 gallium nitrate 62 acromegalic patients 62 pT3 62 Histopathological 62 genomic alterations 62 Hypotension 62 elevated CRP 62 lymphocytic 62 Hodgkin lymphoma HL 62 chlamydial infection 62 Ultrasonographic 62 SIBO 62 Ultrasonography 62 Cardiolite ® 62 HepG2 cells 62 bronchoalveolar lavage 62 bladder cancers 62 receptor inhibitor 62 preoperative chemotherapy 62 promoter methylation 62 lichen planus 62 Anaplastic 62 lung carcinomas 62 antiresorptive 62 platelet inhibitor 62 infliximab Remicade 62 2 diabetes T2D 62 paraganglioma 62 FDG PET scans 62 herpesviruses 62 urethral stricture 62 antiphospholipid antibodies 62 serum prostate 62 presymptomatic 62 benign neoplasms 62 acute myelogenous leukemia AML 62 uricase 62 KRAS mutations occur 62 Alequel 62 completely resected 62 colon carcinoma 62 IDH1 mutation 62 extracranial 62 pharmacodynamic effects 62 transcranial Doppler 62 transthoracic 62 leukocyte counts 62 secretin 62 PSADT 62 neoplastic lesions 62 systemic lupus erythematosus SLE 62 LHRH agonist 62 AGHD 62 antitumour activity 62 testicular tumors 62 nonischemic 62 Mitomycin C 62 cediranib 62 idiopathic PAH 62 grade serous ovarian 62 artery embolization 62 tumor xenograft models 62 alanine aminotransferase ALT 62 PNET 62 haematological cancers 62 acute humoral rejection 62 osteoid 62 intraventricular 62 malignant neoplasms 62 Immunohistochemistry 62 ^ sup #m 62 thromboembolic events 62 predictive biomarker 62 electrophysiologic 62 microvascular dysfunction 62 colorectal polyps 62 anterior uveitis 62 hyperplastic polyps 62 fibrotic disease 62 EGFR TKIs 62 cardiac perfusion 62 Ischemic 62 Prostatic 62 conformal radiotherapy 62 virotherapy 62 Leydig cell 62 preoperative PSA 62 troponin T 62 thymectomy 62 thrombotic complications 62 choriocarcinoma 62 thyroid nodule 62 relapsed ovarian cancer 62 BENICAR HCT 62 acute aortic dissection 62 serum testosterone 62 transferrin saturation 62 lesional 62 transarterial chemoembolization 62 atherogenic dyslipidemia 62 TRUS 62 mesotheliomas 62 gene rearrangement 62 prognostic markers 62 ON #.Na 62 CBLC# 62 liposome formulation 62 Acute Myeloid Leukaemia AML 62 tumoral 62 atypical hyperplasia 62 ultrasonographic examination 62 fulvestrant 62 abnormal cytology 62 chromosomal aberrations 62 Estradiol 62 pathophysiological effects 62 colorectal tumors 62 cyclin E 62 subclinical disease 62 hypoxic tumors 62 stage IIIA 62 Non inferiority 62 leukocytosis 62 PsA 62 Venous thromboembolism 62 intestinal polyps 62 immunoreactivity 62 experimentally induced 62 E. faecalis 62 neoadjuvant chemotherapy 62 juvenile idiopathic arthritis JIA 62 micafungin 62 cinacalcet 62 surrogate markers 62 PREZISTA r 62 keloid scarring 62 graft dysfunction 62 excisional biopsy 62 extramedullary 62 undergone radical prostatectomy 62 myeloablative 62 metabolomic profiles 62 essential thrombocythemia 62 transurethral resection 62 BRAF mutation 62 carotid artery stenosis 62 Leukemias 62 patients undergoing CABG 62 radiolabeled 62 malignant fibrous histiocytoma 62 sarcomatoid 62 neuroregenerative 62 antiemetics 62 Akt activation 62 isoenzyme 62 lactate dehydrogenase 61 transgene expression 61 multicentric 61 Doxil ® 61 clomipramine 61 HepDirect prodrug 61 spontaneous regression 61 chemoresistant 61 Epidermal Growth Factor Receptor 61 cytoreductive nephrectomy 61 TT genotype 61 hypercalciuria 61 ximelagatran 61 supratentorial 61 neurological manifestations 61 dose atorvastatin 61 Neoadjuvant chemotherapy 61 GRASPA ® 61 proliferative retinopathy 61 astrocytoma 61 radioiodine therapy 61 pulmonary toxicity 61 lung metastases 61 adenomatous polyps 61 TNFalpha 61 Myelodysplastic Syndrome MDS 61 radical cystectomy 61 urine dipstick 61 effector function 61 myeloproliferative disorder 61 DFMO 61 Chronic Prostatitis 61 ImmuKnow 61 ventricular myocardium 61 dysglycemia 61 recurrent ovarian cancer 61 antibody MAb 61 chronic periodontitis 61 natriuretic peptide 61 advanced adenomas 61 Teriflunomide 61 refractory metastatic 61 elevated ALT 61 inhibitor RG# 61 GSTT1 61 perioperatively 61 ELISPOT assay 61 mammographically 61 genetic variants associated 61 monoclonal anti 61 androgen dependent 61 Histopathologic 61 refractory ovarian cancer 61 NPM1 mutation 61 endocrine tumors 61 plasma lipid 61 distant metastases 61 carotid plaque 61 repolarization 61 Elevated serum 61 NATRECOR ® 61 follicular lymphoma FL 61 prospective multicentre 61 colorectal adenomas 61 erlotinib Tarceva 61 BCG refractory 61 isoproterenol 61 Helicobacter pylori infection 61 advanced neoplasia 61 malignant lymphomas 61 APTIMA HPV 61 thromboembolic 61 latent tuberculosis TB 61 needle aspiration 61 Radiofrequency ablation 61 seminal vesicle invasion 61 PIB PET 61 Pharmacokinetic studies 61 metastatic RCC 61 osteochondroma 61 Multiple logistic regression 61 antimitotic 61 oncologic outcomes 61 epithelioid 61 IV bisphosphonates 61 pyridostigmine 61 hyperintensity 61 Trandolapril 61 HBeAg 61 vulvar intraepithelial neoplasia 61 MVA MUC1 IL2 61 FluCAM arm 61 intraepithelial neoplasia 61 NNRTI resistance 61 protein tyrosine phosphatase 61 Chronic pancreatitis 61 xenograft tumors 61 Adenomas 61 grade cervical dysplasia 61 antithrombotic agents 61 testicular germ cell 61 Multivariate analysis 61 gastrointestinal stromal tumor 61 cerebral infarction 61 myocardial perfusion 61 histological subtypes 61 guaiac 61 selective agonist 61 edifoligide 61 transient elastography 61 clinicopathologic 61 cytopenias 61 Severe Primary IGFD 61 choroidal vasculopathy 61 antitrypsin 61 PAOD 61 serum markers 61 endothelial activation 61 biomarker assay 61 taxane therapy 61 nondiabetic patients 61 Microalbuminuria 61 pharmacodynamic markers 61 EpCAM 61 UGT#A# 61 pancreatic prostate 61 coronary calcification 61 Main Outcome Measure 61 Xelox 61 Faslodex 61 mouse xenograft models 61 perfusion defects 61 immunoblotting 61 antiestrogen 61 autoimmune thyroid 61 grade glioma 61 metastatic colorectal 61 redox active 61 platelet reactivity 61 CIN3 61 irinotecan chemotherapy 61 rFVIIa 61 paraneoplastic 61 urinary N telopeptide 61 gemcitabine Gemzar ® 61 acute GvHD 61 underwent coronary angiography 61 velafermin 61 vWD 61 EGFR TKI 61 Nilotinib 61 hepatic liver 61 PCA3 gene 61 antithymocyte globulin 61 breast endometrial 61 logistic regression analysis 61 oxysterols 61 SNP rs# [001] 61 B7 H3 61 thyroid stimulating hormone 61 squamous cell lung cancer 61 indibulin 61 cardiac biomarkers 61 clinically meaningful reductions 61 polyp recurrence 61 deletion 5q 61 serum selenium 61 subchronic 61 recurrent acute pancreatitis 61 Sentinel lymph node 61 HAAH 61 conditional logistic regression 61 GORE TAG Device 61 geographic atrophy 61 baseline LDH 61 colonic polyps 61 acute promyelocytic leukemia APL 61 direct thrombin inhibitors 61 cytogenetic abnormalities 61 hypogonadotropic hypogonadism 61 Cystectomy 61 nonrandomized